We thoroughly explore the mechanisms of ICIs, analyze their utilization in both adult and pediatric cancers, and investigate two potential avenues for advancing the use of ICIs in pediatric patients: hypermutated cancers and SMARCB1-deficient tumors. The gene discussed is SMARCB1; the disease is cancer.